IMATINIB NEAPOLIS 100 MG BT 60

Treatment of adult and pediatric patients with chronic myeloid leukemia Ph+ (CML Ph+) in chronic, accelerated phase as well as blast crisis.

Treatment of adults and pediatric patients with acute lymphoid leukemia Ph+ (ALL Ph+) in conjunction with standard chemotherapy.

Treatment of adult patients with hypereosinophilic syndrome (HES), atypical myelodysplastic/myeloproliferative diseases (MDS/MPD) or aggressive subtype of systemic mastocytosis (SM) associated with eosinophilia and either a mutation of the platelet-derived growth factor receptor (PDGF) alpha or beta, or a FIP1L1-PDGF-alpha fusion protein.

Treatment of non-resectable and/or metastatic malignant gastrointestinal stromal tumors (GIST) in adults. - Adjuvant treatment in adults with a significant risk of recurrence after resection of GIST c-Kit (CD 117) positive: patients with a low risk of recurrence should not receive adjuvant treatment.

Treatment of adults with unresectable, recurrent or metastatic dermatofibrosarcoma protuberans (DFSP).